Sonny Bill Williams, Adil Rashid and Muhamed Besic speak to BBC Sport's Shamoon Hafez about observing Ramadan during lockdown.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
According to the Jammu & Kashmir Police, the encounter took place at a village in the Khud-Hanjipora area early on Monday. Security forces had received inputs about the presence of militants in the area late on Sunday night, officers said.
Hello, everyone still stuck at home! Are you in search of new forms of entertainment to free your mind from existential dread? Well, you’ve come to the right place. These are the new Blu-ray releases (and digital releases, too) you should check out this week.…
CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received favorable opinions from the Finnish Medicines Agency (FIMEA) and National Committee on Medical Research Ethics (TUKIJA) to commence its Phase 3 study to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). "Finland is the first of seven European countries in which we plan to open clinical sites as we conduct our AD04 Phase 3 trial in AUD subjects with certain target genotypes related to the serotonin transporter and receptor genes, which appeared to correlate to response to treatment with AD04 in the Phase 2b clinical trial," commented Monika Rogozinska, Chief Development Officer of Adial Pharmaceuticals.
CHARLOTTESVILLE, VA / ACCESSWIRE / April 23, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, ...
CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent by the United States Patent and Trademark Office (USPTO), titled: "Serotonin Transporter Gene and Treatment of Alcoholism." This patent addresses a method of treating alcohol use disorder (AUD) in patients with a specific genetic biomarker in the serotonin transporter gene by administering the Company's investigational new drug product, AD04, a 5-HT3 antagonist, to patients with the TT genotype.
CHARLOTTESVILLE, VA / ACCESSWIRE / February 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
CHARLOTTESVILLE, VA / ACCESSWIRE / March 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that, effective immediately, the Company is modifying its pivotal Phase 3 clinical trial of the Company's lead drug candidate, AD04, for the treatment of alcohol use disorder (AUD) in genetically targeted patients. In order to better protect subjects enrolled in the Phase 3 clinical trial during the COVID-19 pandemic, the Company is in the process of modifying its protocol to reduce the number of in-person visits to clinical sites and replace certain visits with tele-medicine behavioral treatments and assessments. European regulators have encouraged sponsors of clinical trials to take action to reduce travel and potential exposure of study subjects and have indicated receptivity to modifications that achieve this end.
CHARLOTTESVILLE, VA / ACCESSWIRE / February 14, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, is pleased to announce that the Company's CEO, William Stilley, has been selected as a luncheon keynote speaker for the 2020 Wall Street Conference and Retreat to be held in West Palm Beach, Florida on February 19-20. The Company recently announced it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).
A striking composition full of familiar notes, Netflix’s The Eddy brings together an international cast, a BAFTA-winning screenwriter, a Grammy-winning producer, and an auteur whose films reveal a preoccupation with single-minded pursuits. The eight-part limi…
CHARLOTTESVILLE, VA / ACCESSWIRE / October 29, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed the final packaging of its lead investigational drug product, AD04 for the treatment of alcohol use disorder ("AUD"), for use in its planned Phase 3 trial of AD04 (the "Trial"). As previously announced, the Company has partnered with Catalent Pharma Solutions, a leading global provider of advanced delivery, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, to advance clinical activities related to AD04, including packaging and distribution.
85 repair shop operators have been allowed to open for trucks carrying essential items
Central Railway (CR) officials said the decision to run the train from LTT was taken as per the demand raised by the state government. Those onboard were mostly migrant workers from around Jogeshwari.
From the World Cup to the Champions League, Pippo Inzaghi has won it all. He is an AC Milan hero, a goalscorer extraordinaire, the man for the big occasion. Just ask Liverpool.
How are sports stars coping with Ramadan in lockdown? BBC Sport speaks to Sonny Bill Williams, Adil Rashid and Muhamed Besic.
CHARLOTTESVILLE, VA / ACCESSWIRE / December 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted Clinical Trial Applications (CTAs) to commence its first Phase 3 trial in Finland, Estonia, Latvia, Poland, Bulgaria, and Croatia. This follows the Company's recent filing of a CTA to also commence its first Phase 3 trial in Sweden, as previously announced. The planned Phase 3 trial will test AD04 as a genetically-targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).
CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (ADIL)(ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it received an Issue Notification for the issuance of a patent by the United States Patent and Trademark Office (USPTO) for the treatment of Opioid Use Disorder (OUD) with its lead drug candidate, AD04, in people that are positive for select genotypes identified using the Company's propriety companion genetic test. Including the patent term adjustment provided in the Issue Notification, the patent is expected to provide commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions.
Giving details of the joint operation by security forces that ledto the killing of Naikoo, police sources said the Hizbul Mujahideen commander was hiding in the attic that had been covered with a false ceiling.
A J&K Police spokesperson said on Monday that joint forces busted a hideout from a shop owned by Nazir Ahmad Wani at Bellow Dhargund in Pulwama. The police release issued on Monday has come two days after the forces conducted search at the official’s house.
CHARLOTTESVILLE, VA / ACCESSWIRE / April 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that U.S. Patent Number 10,619,209, titled "Serotonin Transporter Gene and Treatment of Opioid-Related Disorders" issued on April 14, 2020. This patent covers the treatment of Opioid Use Disorder by administering the Company's investigational new drug product, AD04, an antagonist of the serotonin-3 receptor (5-HT3), to patients with the LL and TT genotypes, which may be identified by Adial's proprietary genetic test. The gene responsible for encoding the serotonin transporter (SERT), SLC6A4, located on the chromosome 17q11.1-q12, is the only known gene encoding the serotonin transporter and has a functional polymorphism at the 5'-regulatory promoter region, which results in two forms, long (L) or short (S).
Mr. Pearl, the 38-year-old South Asia bureau chief for The Wall Street Journal, was abducted and beheaded while he was in Pakistan investigating a story in 2002
Damien Chazelle's first work for television is an ill-fitting mashup of somber crime story and love letter to live music
CHARLOTTESVILLE, VA / ACCESSWIRE / May 4, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced ...
OFI Crete forward Adil Nabi says he is "itching" to return to action with the Greek Super League scheduled to restart in a fortnight after the Europe-wide suspension of football due to the coronavirus.
The U.S. has again granted Iraq only a month-long sanctions waiver enabling the government to continue importing gas and electricity from Iran, two Iraqi off...
Muslims, critics decry double standard as there were fewer warnings against gathering for events such as VE Day parties.
The police are harassing, beating and even killing people while enforcing COVID-19 lockdowns across the world.
CHARLOTTESVILLE, VA / ACCESSWIRE / April 16, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that the functionality of its proprietary companion diagnostic genetic test has been verified as clinically effective through its utilization in the landmark ONWARD™ pivotal Phase 3 clinical trial of the Company's lead drug candidate, ultra-low dose ondansetron (AD04), for the treatment of Alcohol Use Disorder (AUD). The Company expects to expand the use of the genetic test into clinical trials of AD04 in the future for the treatment of other indications such as Opioid Use Disorder (OUD) and is working to establish testing capacity in the United States for future studies.
CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed validation of its genetic biomarker test for its planned Phase 3 trial. The Phase 3 trial is designed to study AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder. Eurofins Genomics ("Eurofins"), a division of Eurofins Biopharma Services, a global scientific leader in bioanalytical testing, performed the laboratory validation of Adial's companion diagnostic genetic test using double strand Sanger sequencing and Fragment length analysis of polymerase chain reaction (PCR) products.
Ranvir Singh, in his 30s, was declared dead on arrival at the local hospital. Officials said it was a natural death.
CHARLOTTESVILLE, VA / ACCESSWIRE / April 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its landmark ONWARD™ Phase 3 pivotal trial of its lead drug candidate, AD04, in genetically identified subjects for the treatment of Alcohol Use Disorder (AUD). The number of in-clinic visits per subject has been reduced from 19 to 8.
CHARLOTTESVILLE, VA / ACCESSWIRE / October 1, 2019 / Adial Pharmaceuticals, Inc. (ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted its Clinical Trial Application (CTA) to commence the Phase 3 clinical trial of the Company's lead drug candidate, AD04, (the "Phase 3 Trial" or the "Trial") for the treatment of alcohol use disorder (AUD) in genetically targeted patients with the Swedish Medical Products Agency. "The filing of our CTA marks another important milestone, as we continue to execute on our plan," stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals.
The genetic biomarker is part of the genetic panel used to identify patients for inclusion in Adial's Phase 3 trial of AD04 for the treatment of AUD in genetically targeted patients. William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "This Notice of Allowance by the USPTO is another important milestone as we progress towards Adial's planned Phase 3 trial of AD04 and further solidifies the patent estate around AD04.
Whenever you eliminate the leadership, it will definitely bring down militant recruitment, says Kashmir IGP Vijay Kumar.
The security forces, comprising of Jammu and Kashmir Police and CRPF, were fired upon by the militants during the search operation and the exchange of fire is underway.
CHARLOTTESVILLE, VA / ACCESSWIRE / February 19, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approval to commence its Phase 3 study to investigate AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in Bulgaria in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes receiving approvals from both the Bulgarian Drug Agency and the Bulgarian Ethics Committee for Clinical Trials overseeing the study. "Bulgaria is expected be an important country in our Phase 3 trial of AD04 in biomarker-positive study participants," stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that Mark Howard Peikin, Esq., Chief Executive Officer of Bespoke Growth Partners (Bespoke), and a former General Partner of Aelius Healthcare Innovations Fund and partner within the corporate and securities group at the international law firm Brown Rudnick, was appointed as Chief Strategy Officer and Vice President of Corporate Communications. As Adial conducts its European Phase 3 clinical trial of AD04 for the treatment of Alcohol Use Disorder (AUD), which trial will study subjects for 24-weeks with 290 subjects projected to be enrolled in approximately 30 clinical sites in 7 European countries, Mr. Peikin will help oversee Adial's discussions with pharmaceutical companies, as well as strategic and institutional investors.